Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice

FEBS Letters

Volumn 583, Issue 12, 2009, Pages 1859-1866

  Jin, Lin ^a   Xiao, Chuan Le ^a   Lu, Chun Hua ^a   Xia, Min ^b   Xing, Guo Wen ^c   Xiong, Sheng ^a   Liu, Qiu Ying ^a   Liu, Hui ^a   Li, Yi Cheng ^a   Ge, Feng ^a   Wang, Qing Duan ^d   He, Qing Yu ^a   Wang, Yi Fei ^a  

^a JINAN UNIVERSITY   (China)

^b Beijing Guoyaolongli Biomedicine New Technology Co Ltd   (China)

^c BEIJING NORMAL UNIVERSITY   (China)

^d Henan Academy of Sciences   (China)

Author keywords

Apoptosis; K562 cell; Mitochondria dysfunction; Proteomic; SNX 2112; Transcriptomic

Indexed keywords

ANTILEUKEMIC AGENT; CASPASE; PROTEIN KINASE B; SNX 2112; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SCID MOUSE; SIGNAL TRANSDUCTION; SURVIVAL TIME; TRANSCRIPTOMICS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; GENE EXPRESSION PROFILING; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED NOD; MICE, SCID; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 67349255247     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.04.046     Document Type: Article

References (34)

1. Maloney A., and Workman P. Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Exp. Opin. Biol. Ther. 2 (2002) 3-24
2. Ruden D.M., Xiao L., Garfinkel M.D., and Lu X. Hsp90 and environmental impacts on epigenetic states: a model for the trans-generational effects of diethylstibesterol on uterine development and cancer. Hum. Mol. Genet. 14 (2005) 149-155
3. Chandarlapaty S., et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 14 (2008) 240-248
4. Barta T.E., et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg. Med. Chem. Lett. 18 (2008) 3517-3521
5. Nikitin A., Egorov S., Daraselia N., and Mazo I. Pathway studio the analysis and navigation of molecular networks. Bioinformatics 19 (2003) 2155-2157
6. Pastorino J.G., Tafani M., and Farber J.L. Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway. J. Biol. Chem. 274 (1999) 19411-19416
7. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., and Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat protein 90. J. Natl. Cancer Inst. 91 (1999) 1940-1949
8. Nicholson D.W., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 3-43
9. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 326 (1997) 1-16
10. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
11. Budihardjo I., Oliver H., Lutter M., Luo X., and Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15 (1999) 269-290
12. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39 (2005) 359-407
13. Tang T., Zheng B., Chen S.H., Murphy A.N., Kudlicka K., Zhou H.L., and Farquhar M.G. HNOA1 interacts with complex I and DAP3 and regulates mitochondrial respiration and apoptosis. J. Biol. Chem. 284 (2009) 5414-5424
14. Sánchez-Alcázar J.A., Khodjakov A., and Schneider E. Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res. 61 (2001) 1038-1044
15. Cimini D., Patil K.R., Schiraldi C., and Nielsen J. Global transcriptional response of Saccharomyces cerevisiae to the deletion of SDH3. BMC Syst. Biol. 3 (2009) 17
16. Hansson A., Hance N., Dufour E., Rantanen A., Hultenby K., Clayton D.A., Wibom R., and Larsson N.G. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc. Natl. Acad. Sci. USA 101 (2004) 3136-3141
17. Kropotov A., Usmanova N., Serikov V., Zhivotovsky B., and Tomilin N. Mitochondrial targeting of human peroxiredoxin V protein and regulation of PRDX5 gene expression by nuclear transcription factors controlling biogenesis of mitochondria. FEBS J. 274 (2007) 5804-5814
18. Banmeyer I., Marchand C., Clippe A., and Knoops B. Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. FEBS Lett. 579 (2005) 2327-2333
19. Petrat F., Paluch S., Dogruoz E., Dorfler P., Kirsch M., Korth H.G., Sustmann R., and de Groot H. Reduction of Fe(III) ions complexed to physiological ligands by lipoyl dehydrogenase and other flavoenzymes in vitro: implications for an enzymatic reduction of Fe(III) ions of the labile iron pool. J. Biol. Chem. 278 (2003) 46403-46413
20. Sy L.K., Yan S.C., Lok C.N., Man R.Y., and Che C.M. Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res. 68 (2008) 10229-10237
21. He X.Y., Yang S.Y., and Schulz H. Inhibition of enoyl-CoA hydratase by long-chain L-3-hydroxyacyl-CoA and its possible effect on fatty acid. Arch Biochem. Biophys. 298 (1992) 527-531
22. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278 (2003) 37832-37839
23. Montesano G.N., Chirico G., Pirozzi G., Costantino E., Landriscina M., and Esposito F. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 10 (2007) 342-350
24. Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu. Rev. Biochem. 54 (1985) 1015-1069
25. Reed J.C. Cytochrome c: can't live with it - can't live without it. Cell 91 (1997) 559-562
26. Patel H., Marley S.B., and Gordon M.Y. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 45 (2006) 1121-1129
27. Sattler M., et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12 (1996) 839-846
28. Rao R., et al. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112 (2008) 1886-1893
29. Barnes D.J., De S., van Hensbergen P., Moravcsik E., and Melo J.V. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Leukemia 21 (2007) 421-426
30. Park T.J., and Curran T. Crk and Crk-like play essential overlapping roles downstream of disabled-1 in the Reelin pathway. J. Neurosci. 28 (2008) 13551-13562
31. Dance M., Montagner A., Yart A., Masri B., Audigier Y., Perret B., Salles J.P., and Raynal P. The adaptor protein Gab1 couples the stimulation of vascular endothelial growth factor receptor-2 to the activation of phosphoinositide 3-kinase. J. Biol. Chem. 281 (2006) 23285-23295
32. Zandy N.L., and Pendergast A.M. Abl tyrosine kinases modulate cadherin-dependent adhesion upstream and downstream of Rho family GTPases. Cell Cycle 7 (2007) 444-448
33. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
34. Wolff N.C., and Ilaria Jr. R.L. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 98 (2001) 2808-2816